Taro Recovering From Profit Shortage Following Branded OTC Promotions
This article was originally published in The Tan Sheet
Executive Summary
A steady increase in sales and lowering of costs in the second half of 2004 show Taro is recovering from profit shortages that stemmed in part from promotional spending on its branded OTC products, the firm says
You may also be interested in...
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC